Flores LNH, Rubio GAF, Huerta RS

Language: Spanish
References: 15
Page: 546-551
PDF size: 201.09 Kb.

ABSTRACT

Background: Ankle/brachial index (ABI) ‹0.09 is a marker of peripheral vascular disease and a predictor of cardiovascular morbidity and mortality. Currently, despite that heart disease is the leading cause of death in diabetic patients, the effect of oral hypoglycemic drugs on cardiovascular risk is not evaluated.
Methods: In this controlled clinical trial, we included 68 normotensive diabetic type 2 patients. One group was treated with glibenclamide (36 patients) and another with repaglinide (32 patients), metformin was added when necessary. In both groups ABI, fasting glucose and lipid profile were evaluated at baseline and after 3 months follow-up.
Results: 43% female, mean age 52.66 years. 25 patients in each group received combination with metformin. The ABI with glibenclamida increased of 1.17 to 1.19 p=0.4764 and with repaglinide from 1.16 to 1.21 p= 0.1338, when comparing both groups, although the increase was higher with repaglinida, the difference was not significant, (p=0.0786). HbA1c decreased from 9.19% to 8.29% with glibenclamide, p=0.0733 and 10.71% to 7.74% with repaglinide, p=0.00001, when comparing both groups there was a significant difference in favor of repaglinide, p=0.0026.
Conclusions: In this study we found that repaglinide achieved better control of HbA1c than glibenclamide, and that both drugs improved the ABI, although this improvement showed a trend to a further increase with repaglinide, it does not reach statistical significance.

REFERENCES

1. Stratton IM, Adler AI, Nel HAW, Matthews DR, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35); prospective, observational study. BMJ 2000;321:405-412.

2. Standars of medical care in diabetes 2009. Diabetes Care 2009;32 supplement 1.

3. Saudek CD, Derr RL, Kalyani RR. Assessing glycaemia in diabetes using self-monitoring blood glucose and hemoglobin A1c. JAMA 2006;295:1688-1697.

4. Hamilton SJ. Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus. Diab Vasc Dis Res 2007;4:89-102.

5. Koski RR. Oral antidiabetic agents: a comparative review. J Pharmacy Prac 2004;17:39.

6. Bicklé JF. Meglitinide analogues: a review of clinical data focused on recent trials. Diabetes Metab 2006;32:113-120.

7. Robert M. Fixed combination of repaglinide and metformin in the management of type 2 diabetes; Diabetes, Metabolic syndrome and Obesity. Targets and Therapy 2009;2:101-109.

8. Allison BG. Assessing the cardiovascular safety of diabetes therapies. N Eng J Med 2008;359:1092-1095.

9. Scarsi M, Podvinec M, Roth A, et al. Sulfonylureas and Glinides Exhibit Peroxisome Proliferator Activated Receptor gamma Activity: A combined Virtual Screening and Biological Assay Approach. Mol Pharmacol 2007;71:398-406.

10. Pearson T, Kukulka G, Rahman ZU. Ankle brachial index measurement in primary care setting: how long does it take? South Med J 2009;102:1106-1110.

11. Päivi E, Korhonen KT, Syvänen RK, Vesalainen IM, et al. Anklebrachial index is lower in hypertensive than in normotensive individuals in a cardiovascular risk population. J Hypertens 2009;27:2036-2043.

12. Schweizer A, Ball M, Owens DR, Cressier F, et al. Comparison of the postprandial glucose and insulin profiles with nateglinide and gliclazide in type 2 diabetic patients. Br J Diabetes Vasc Dis 2002;2:228-232.

13. Pale-Torres LJ, Lozano-Nuevo JJ, Rubio-Guerra AF. Indice brazo tobillo y albuminuria en pacientes normotensos. Rev Med Inst Mex Seguro Soc 2011;49:311-314.

14. Kollias A, Xilomenos A, Protogerou A, Dimakakos E, Stergiou GS. Automated determination of the ankle-brachial index using an oscillometric blood pressure monitor: validation vs. Doppler measurement and cardiovascular risk factor profile. Hypertens Res 2011;34:825-830.

15. Hamilton SJ, Chew GT, Watts GF. Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus. Diab Vasc Dis Res 2007;4:89-102.